APOH and COVID-19: This study found that critically ill COVID-19 patients had higher levels of anticardiolipin antibodies than non-critically ill patients (28.8% vs 7.1%; p<0.0001), and similarly significantly higher levels of anti-beta-2 glycoprotein 1 antibodies (12.0% vs 5.8%, p<0.0001).